Kurs & Likviditet
Beskrivning
Land | Danmark |
---|---|
Lista | First North Stockholm |
Sektor | Hälsovård |
Industri | Bioteknik |
Hørsholm, Denmark, January 27, 2021 - ExpreS2ion Biotech Holding AB ("ExpreS2ion") hereby announces that Aktiespararnars' Analysguiden has published an updated equity research report on ExpreS2ion. The updated sum-of-the-parts valuation base case remains at 24 SEK per share.
The major contributors of value in the sum-of-the-parts valuation are the PREVENT-nCoV COVID-19 vaccine program, now designated ABNCoV2 under exclusive license to Bavarian Nordic, and ExpreS[2]ion's planned exercise of the option to inlicense the AV001/ES2B-C001 breast cancer vaccine candicate from its joint venture partner AdaptVac ApS.
The full English version of the company-sponsored equity research report is attached to this press release, while the Swedish version is available on Analysguiden's website: https://www.aktiespararna.se/analysguiden/Hitta-Bolag/health-care/expres2ion-biotech-holding/analys.
Certified Adviser
Svensk Kapitalmarknadsgranskning AB
Telefon: +46 11 32 30 732
E-post: ca@skmg.se